New tetanus shot enters human safety testing
NCT ID NCT07149454
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new lab-made antibody injection against tetanus in 68 healthy adults aged 18-60. The main goal is to check safety and side effects, not to treat or prevent tetanus directly. Participants receive a single shot and are monitored for several weeks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TETANUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Lanzhou Institute of Biological Products Co., Ltd.
Lanzhou, Gansu, 730000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new vaccine shield older kids and adults from three deadly infections?
- Can a Five-Part vaccine bolster protection against three serious infections?
- Can a single shot keep tetanus at bay?
- Will a single DTP vaccine dose protect for a decade? study tracks antibodies
- Can a new tetanus shot offer stronger protection?
- Are adults in beijing still protected against tetanus? a study investigates